Fiche société
Chongqing Precision Biotech Co., Ltd
Traitements, essais et publications liés.
Traitements2programmes
Essais1liés
Publications9liées
SourceDBlocale
Traitements
2| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| CD19 CAR-T cellsThis is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous CD19-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus. | Lupus | Phase 1 | Thérapie cellulaire | China | À vérifier |
| CD19 CAR-T cellsThis is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous CD19-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus. | Lupus | Phase 1 | Thérapie cellulaire | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| CD19 CAR-T cells | Lupus | Phase 1 | NCT07331467 | Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE | RECRUITING |
Publications
9| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| CD19 CAR-T cells | Coated oncolytic viruses based "double strike" strategy triggering CD19 CAR-T therapy in gastrointestinal tumors. | Biomaterials | ||
| CD19 CAR-T cells | CAR T cells for systemic autoimmune diseases. | Autoimmunity reviews | ||
| CD19 CAR-T cells | Engineering T cells in vivo to express a synthetic cytokine receptor enables preferential expansion and enrichment of anti-CD22 CAR T cells. | Molecular therapy : the journal of the American Society of Gene Therapy | ||
| CD19 CAR-T cells | Real-World Data from a Single-Center, Large Academic Centralized Manufacturing of CD19 CAR T Cells in an Industry Partnership. | Human gene therapy | ||
| CD19 CAR-T cells | Reply:BCMA-CD19 CAR T Cells in Systemic Lupus Erythematosus: Humoral Reset or Antigen-Specific Tolerance? | Arthritis & rheumatology (Hoboken, N.J.) | ||
| CD19 CAR-T cells | Coordinated expansion of CD163⁺ monocytes and immature CD177⁺ neutrophils marks severe neurotoxicity after CD19 CAR T cell therapy. | bioRxiv : the preprint server for biology | ||
| CD19 CAR-T cells | Expansion and safety profile of CD28-costimulated anti-CD19 CAR T cells in B-cell lymphoma versus autoimmune disease. | HemaSphere | ||
| CD19 CAR-T cells | CAR T Cell Therapy as a Definitive Consolidation for Older Adults with B-ALL in First Complete Remission. | Blood advances | ||
| CD19 CAR-T cells | Infections within 100 days of idecabtagene vicleucel and impact on survival for relapsed/refractory multiple myeloma: A CIBMTR Analysis. | Transplantation and cellular therapy |